BioSpace News Archive

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX) today announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of 2024 and provided a summary of recent corporate highlights.

Next Gen Diagnostics and a team at Vanderbilt University Medical Center announced the results of a study reporting that comparison of the whole genome sequence of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit revealed substantial transmission of infection not detected by conventional infection control procedures.

Cali Biosciences Co., Ltd. announced publication of “CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair” in the scientific journal Hernia.

Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, announced an oral presentation by Professor Evan Dellon M.D., M.P.H, at the Digestive Disease Week 2024 Annual Scientific Meeting.

Molecular Targeting Technologies, Inc., will update findings on both 177Lu-EBTATE clinical and 225Ac-EBTATE preclinical work during the 2024 SNMMI meeting in Toronto June 8-11.

Ventegra, Inc. announces it is the first to earn 2024 certification from HPfid’s newly launched program that demonstrates that the awardees comply with the fiduciary requirements of the Consolidated Appropriations Act, 2021.

BioXcel Therapeutics, Inc. announced that Rob Risinger, M.D., Chief Medical Officer of Neuroscience, will deliver oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.

Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.